UPDATE: Morgan Stanley Downgrades Axsome Therapeutics (AXSM) to Equalweight

August 10, 2021 3:34 AM EDT
Get Alerts AXSM Hot Sheet
Price: $46.27 --0%

Rating Summary:
    12 Buy, 1 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 5 | Down: 23 | New: 10
Join SI Premium – FREE
(Updated - August 10, 2021 8:49 AM EDT)

Morgan Stanley analyst Vikram Purohit downgraded Axsome Therapeutics (NASDAQ: AXSM) from Overweight to Equalweight with a price target of $34.00 (from $105.00).

The analyst commented, "An FDA letter noted deficiencies with the NDA for AXS-05 in MDD. With odds of an on-time approval lowered and the risk for a delay or a CRL increased, we now find the set-up for AXSM challenging, particularly given the lack of additional near-term pipeline catalysts."

For an analyst ratings summary and ratings history on Axsome Therapeutics click here. For more ratings news on Axsome Therapeutics click here.

Shares of Axsome Therapeutics closed at $27.34 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

Morgan Stanley, FDA